Last $14.39 USD
Change Today +0.22 / 1.55%
Volume 973.2K
IRWD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 07/9/14 All times are local (Market data is delayed by at least 15 minutes).

ironwood pharmaceuticals inc (IRWD) Key Developments

Ironwood Pharmaceuticals, Inc. Appoints Gina Consylman as Vice President, Corporate Controller and Chief Accounting Officer

Effective June 23, 2014, Ironwood Pharmaceuticals, Inc. appointed Gina Consylman, 42, as its Vice President, Corporate Controller and Chief Accounting Officer. Prior to joining the Company, Ms. Consylman served as Vice President, Corporate Controller and Principal Accounting Officer of Analogic Corporation.

Ironwood Pharmaceuticals, Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 02:00 PM

Ironwood Pharmaceuticals, Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 02:00 PM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States. Speakers: Peter M. Hecht, Co-Founder, Chief Executive Officer and Director.

Ironwood Pharmaceuticals, Inc. Appoints Douglas Williams to Board of Directors

Ironwood Pharmaceuticals, Inc. announced the appointment of Douglas Williams, Ph.D., to its board of directors. Dr. Williams currently serves as executive vice president, research and development for Biogen Idec Inc. and was previously chief executive officer of ZymoGenetics, Inc.

Ironwood Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 01:30 PM

Ironwood Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 01:30 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: James J. O'Mara, Vice President of Corporate Development.

Ironwood Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Reiterates Financial Guidance for the Year 2014

Ironwood Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter ended March 31, 2014, the company reported net loss was approximately $49.6 million, or $0.38 per basic and diluted share as compared to $93.902 million, or $0.87 per basic and diluted share, for the same period last year. Revenue was $14.605 million compared to $3.255 million for the same period last year. Loss from operations was $44.387 million compared to $88.833 million for the same period last year. The company ended the first quarter of 2014 with approximately $332 million of cash, cash equivalents and available-for-sale securities, up from approximately $198 million as of the end of 2013. The company used $58 million in cash for operations during the quarter. The company reiterated its financial guidance for the year 2014. For the year, the company expects total operating expenses to be in the range of $215 million to $225 million. This consists of $105 million to $120 million of R&D expenses, of which, approximately 45% is for [indiscernible] R&D investments and $110 million to $125 million of SG&A expense.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRWD:US $14.39 USD +0.22

IRWD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $4.54 USD +0.06
Nektar Therapeutics $12.13 USD -0.02
Progenics Pharmaceuticals Inc $4.28 USD +0.13
Sucampo Pharmaceuticals Inc $6.89 USD -0.07
Theravance Inc $29.00 USD -0.30
View Industry Companies
 

Industry Analysis

IRWD

Industry Average

Valuation IRWD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 53.7x
Price/Book 10.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 42.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRONWOOD PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.